BioCentury
ARTICLE | Clinical News

INCB19602: Phase I data

January 14, 2008 8:00 AM UTC

In a Phase I trial in healthy volunteers, INCB19602 was well-tolerated and reduced free fatty acid levels without causing cutaneous flushing. ...